This Article Full Text (PDF) Other Versions of this Article: AAC.01454-07v1 52/5/1837    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Faúndez, M. Articles by Maya, J. D. PubMed PubMed Citation Articles by Faúndez, M. Articles by Maya, J. D.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01454-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Buthionine sulfoximine has anti-T.cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox

Program of Molecular and Clinical Pharmacology, ICBM, Faculty of Medicine, University of Chile; Program of Anatomy and Developmental Biology, ICBM, Faculty of Medicine, University of Chile; Facultad de Farmacia, Universidad de Valparaíso, Chile

^* To whom correspondence should be addressed. Email: jmaya{at}med.uchile.cl.

	Abstract

L-Buthionine (S,R)-sulfoximine (BSO) at a dose of 220 mg/Kg/day showed an anti-T. cruzi effect in mice, increasing the survival rate and decreasing the parasitemias and parasite burden in the hearts. BSO plus Nifurtimox (Nx) treatment caused an increase in survival rate compared with treatment with each drug alone.